Want to see TSE:MSCL full AI Analyst Report?
Top Page
Satellos Bioscience
(TSX:MSCL)
Select Model
Select Model
Rating:42Neutral
Price Target:
C$9.50
▼(-27.37% Downside)
Action:Reiterated
Date:10/14/26
The score is weighed down primarily by weak financial performance (no revenue, widening losses, and significant cash burn), with additional pressure from bearish technical trends (below major moving averages and negative MACD). Valuation contributes limited support because the company is loss-making (negative P/E) and no dividend yield is provided.
Positive Factors
Regenerative medicine pipeline
The company targets a significant unmet need in skeletal muscle disorders through a focused regenerative-medicine approach. Progress in restoring muscle repair could create differentiated therapeutic value and support a durable commercial opportunity if clinical development succeeds.
Negative Factors
No revenue generation
The absence of revenue means the company has not yet demonstrated commercial traction or internally generated funding for operations. Its financial outlook therefore remains dependent on clinical progress and external capital until a product reaches the market.
Read all positive and negative factors
Positive Factors
Negative Factors
Regenerative medicine pipeline
The company targets a significant unmet need in skeletal muscle disorders through a focused regenerative-medicine approach. Progress in restoring muscle repair could create differentiated therapeutic value and support a durable commercial opportunity if clinical development succeeds.
Read all positive factors
Satellos Bioscience (MSCL) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$197.95M
Dividend YieldN/A
Average Volume (3M)10.54K
Price to Earnings (P/E)―
Beta (1Y)1.13
Revenue GrowthN/A
EPS Growth-6.00%
CountryCA
Employees18
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.14
Shares Outstanding21,216,438
10 Day Avg. Volume10,567
30 Day Avg. Volume10,535
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)4.17
Price to Sales (P/S)0.00
P/FCF Ratio-4.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$34.88Price Target Upside166.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-3.29
Revenue Forecast (FY)N/A
Satellos Bioscience Business Overview & Revenue Model
Company Description
Satellos Bioscience Inc., a biotechnology firm established in 2018 and headquartered in Toronto, Canada, specializes in developing regenerative therapies for degenerative muscle diseases. The company primarily operates in Canada and Australia, uti...
Satellos Bioscience Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
62
Positive
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -7.31M | -5.09K | -20.00K | -8.82M | -3.73M | -165.69K |
| EBITDA | -35.93M | -26.92M | -28.08M | -15.71M | -8.09M | -4.69M |
| Net Income | -34.93M | -25.31M | -28.10M | -15.89M | -11.32M | -15.51M |
Balance Sheet | ||||||
| Total Assets | 65.66M | 31.83M | 73.02M | 44.30M | 6.20M | 12.59M |
| Cash, Cash Equivalents and Short-Term Investments | 61.74M | 27.66M | 69.85M | 39.59M | 1.92M | 4.87M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 5.85M | 4.10M | 5.16M | 3.62M | 2.83M | 2.10M |
| Stockholders Equity | 59.81M | 27.73M | 67.86M | 40.67M | 3.37M | 10.48M |
Cash Flow | ||||||
| Free Cash Flow | -28.76M | -24.02M | -24.98M | -14.52M | -5.79M | -5.04M |
| Operating Cash Flow | -28.76M | -24.01M | -24.98M | -14.50M | -5.78M | -5.03M |
| Investing Cash Flow | -54.10M | -9.58M | 6.34M | -17.54M | -3.00K | 1.74M |
| Financing Cash Flow | 52.16M | 2.28M | 53.48M | 51.03M | 2.77M | 7.45M |
Satellos Bioscience Technical Analysis
Negative
13.08
Price Trends
12.03
Negative
11.63
Negative
11.76
Negative
Market Momentum
-0.88
Positive
33.44
Neutral
14.68
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MSCL, the sentiment is Negative. The current price of 13.08 is above the 20-day moving average (MA) of 10.49, above the 50-day MA of 12.03, and above the 200-day MA of 11.76, indicating a bearish trend. The MACD of -0.88 indicates Positive momentum. The RSI at 33.44 is Neutral, neither overbought nor oversold. The STOCH value of 14.68 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:MSCL.
Satellos Bioscience Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | C$75.61M | -22.50 | -21.54% | ― | ― | 77.30% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | C$58.42M | -20.24 | 74.79% | ― | ― | -15.53% | |
44 Neutral | C$32.60M | -1.91 | -360.29% | ― | ― | -33.27% | |
42 Neutral | C$197.95M | -3.36 | -72.67% | ― | ― | -6.00% |
* Healthcare Sector Average
TSE:MSCL
Satellos Bioscience
9.67
0.43
4.65%
TSE:ARCH
Arch Biopartners
0.87
-0.09
-9.37%
TSE:MDNA
Medicenna Therapeutics Corp
0.43
-1.19
-73.46%
TSE:HBP
Helix BioPharma
1.04
-1.05
-50.24%
TSE:METX
ME Therapeutics Holdings, Inc.
1.06
-3.69
-77.68%
TSE:ONCO
Onco-Innovations Ltd.
1.47
0.00
0.00%
Satellos Bioscience Corporate Events
Business Operations and StrategyPrivate Placements and FinancingProduct-Related Announcements
Satellos Wins FDA Green Light for FSHD Trial and Secures Up to US$5 Million in Non-Dilutive Funding
Positive
Sep 24, 2026
Satellos Bioscience has secured U.S. FDA clearance of its Investigational New Drug application to study forazapadin in facioscapulohumeral muscular dystrophy, expanding the drug’s development into a second degenerative muscle disease with no...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.